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s.2011.06Abstract Numerous drugs show signiﬁcant behavioral, developmental, teratogenic and mutagenic
effects. This study investigates the cytotoxic and genotoxic effects of two doses (20 and 40 mg/kg
body weight) of the antimalarial drug meﬂoquine (MQ), in male mice. The parameters included
the assessment of: mitotic index, cell cycle kinetics, and frequency of chromosomal aberrations in
bone marrow cells, translocation frequency in spermatocytes and head and tail abnormalities in
sperm. A high dose of meﬂoquine resulted in a decreased mitotic index, suggesting a dose–response
correlation. A notable recovery in mitotic activity was observed during the ﬁrst and third week post
treatment, which approached the mitotic index of control. Chromosomal abnormalities including
gaps, breaks, and fragments also increased with the higher dose of meﬂoquine. Spermatids and sec-
ondary spermatocytes were moderately sensitive to the drug; whereas primary spermatocytes were
more sensitive, and spermatogonia were highly sensitive to both doses of MQ.
Conclusion: Meﬂoquine (MQ) at the doses used can be considered as a drug with a potential
mutagenic effect. The results obtained from the spermatocyte diakinesis-metaphase 1 test and sperm
abnormalities suggest that MQ may contribute to high incidence of birth defects and congenital
abnormalities.
ª 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Meﬂoquine, a 4-quinolinemethanol (MQ), is the only drug
proven to be effective against multiple drug-resistant malaria.ology Department, Faculty of
x 22452, Riyadh 11495, Saudi
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.001Experimental studies indicated that meﬂoquine does not sig-
niﬁcantly bind to DNA (Davidson et al., 1975). Schupbach
(1979) showed no mutagenic activity of meﬂoquine in three
tester strains TA 1535, TA 1537 and TA 1538 of Salmonella
typhimurium. Grisolia and Takahashi (1994) showed that
the administration of MQ did not lead to any clastogenic
activity in the bone marrow of Wistar rats, when given in
doses of 150, 300, 600 and 1200 mg/kg, equivalent to the
human therapeutic doses. However, in vitro studies showed
that meﬂoquine at doses (100 and 50 lg/ml) signiﬁcantly
altered poly-morphonuclear neutrophils (PMN) while, amodi-
aquine and chloroquine did not (Labor and Babin-Chevaye,
1988). The genotoxic effect of amodiaquine (AQ), meﬂoquine
(MQ) and halofantrine (HF), investigated in rat liver cellsier B.V. All rights reserved.
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between 0 and 1000 lmol/L signiﬁcantly increased DNA
strand breaks of rat liver cells illustrating dose-dependent
relationship in the order of AQ>MQ>HF (Farombi,
2005, 2006). However, the study of clastogenic activity in
human lymphocytes has not been done, in vitro or in patients
undergoing therapy. Chatterjee et al. (1998), who used similar
groups of three antimalarial drugs to examine the genotoxic
and mutatoxic potential of MQ revealed that these drugs
are weak mutagen, but capable of inducing signiﬁcant sister
chromatid exchange (SCE) and chromosomal aberrations
(CA) in the bone marrow cells of mice. Karbwang and White
(1990) detected the induction of lymphocytopenia at doses of
30 mg/kg. Genotoxicity tests by Akerele and Obaseiki-Ebor
(2002) indicated that MQ was generally not genotoxic,
but had the same potential mutagenicity as chloroquine
phosphate.
The current study was undertaken to examine the long term
treatment on cytotoxic and mutagenic potential of MQ in male
mice, administered at 20 and 40 mg doses. The mitotic index of
bone marrow cells, chromosomal aberration in metaphase cells
and cytogenetic evaluation diakinesis-metaphase 1 in mouse
spermatocytes were the focus of the study. Morphological
abnormalities of the sperm too, were studied over 3 weeks.
Following the last day of the drug treatment, sperms were ana-
lyzed at weekly intervals for 6 weeks, to study the effect of the
drug on each stage of the spermatogenic cycle, which is com-
pleted in about 5 weeks (Okberg, 1956; Wyrobek, 1978).2. Material and methods
2.1. Experimental animals
Swiss albino mice, strain SWR/J, were used in this study.
Adult male mice were obtained from the Central Animal
House of King Saud University (Women’s Branch – Malaz,
Riyadh, KSA). The animals were housed in well ventilated, hy-
gienic conditions under standardized temperatures. Food and
water were provided ad libitum. Male mice were used in order
to avoid hormonal interference of the estrous cycle in females.
All animals were 10–12 weeks of age, each weigh about 25 g.
Animals were randomly selected for experimental control.
2.2. Dosage and treatment
Meﬂoquine (trade name Mephaquine [Mepha Ltd., Aesch-
Basel, Switzerland]) was purchased from a local pharmacy in
Riyadh, KSA, and was suspended in Tween 80 (1%) to the
desired concentrations (1 mg/0.5 ml, and 0.5 mg/0.5 ml).
These doses correspond to human doses of 40 and 20 mg/kg
bodyweight (Preston et al., 1981; Fryauff et al., 2007). The stock
solution was freshly prepared before each dose was
administered.
For studying cytotoxic and cytogenetic effects of bone
marrow (mitotic index, cell cycle kinetics, and chromosomal
aberrations in metaphase cells), animals were divided into
three large groups of 30 animals each: two treated with a dif-
ferent dose of MQ and the third served as the control. Each
large group was divided into six small groups of ﬁve animals
each.For spermatocyte diakinesis metaphase-1 test and for study-
ing themorphological abnormalities of spermhead and tail, ani-
mals were similarly divided into three groups of 35male animals
each. Two groups were treated with a different dose of MQ and
the third group served as control. Each large group was subdi-
vided into seven small groups of ﬁve animals each.
2.3. Sampling time
Cells were obtained from bone marrow of both control and
treated mice. Mitotic indices, cell cycle kinetics, and analysis
of chromosomal aberrations were performed at 24, 48, 72 h
and at weekly intervals for 3 weeks following the last dose.
For the spermatocyte metaphase-1 test, samples were tested
at 24 h and at weekly intervals for 6 weeks following the last
dose of drug, which covered a complete spermatogenic cycle.
Morphological head and tail abnormalities of the spermatozoa
were recorded for 6 weeks at weekly intervals following the last
dose.
2.4. Techniques for the study of mitotic index, cell cycle kinetics,
and metaphase chromosomes from bone marrow cells
Bone marrow from treated and control mice was ﬂushed out
from the two femurs into saline solution. The aspirated cells
were divided into two samples; one was processed immediately
for the study of mitotic index and cell cycle kinetics (Cho et al.,
2011). The second sample is treated with Colchicine for 2 h for
the study of metaphase chromosomal aberrations followed by
hypotonic treatment with 0.075 M KCl for 20 min at 37 C.
Cells were then ﬁxed in Carnoy’s ﬁxative (3:1 methanol:1 ace-
tic acid). Air dried slide preparations were stained with 5%
Giemsa stain (Evans et al., 1964; Adler, 1984). A total diploid
number of chromosomes were counted in 100 metaphases and
different types of CA were determined and tabulated according
to Savage (1975). The effect of MQ on cell cycle kinetics of the
bone marrow cells was also examined.
2.5. Analysis of germinal cell tissue, spermatocyte diakinesis-1,
and morphological abnormalities of head and tail regions of
spermatozoa
To evaluate the effect of MQ on meiotic chromosomes from
germinal cells in different stages of spermatogenesis, treated
animals and control groups were dissected and testes were re-
moved from the seminiferous tubules. The cytogenetic analysis
of diakinesis metaphase-1 spermatocytes involved the detec-
tion of reciprocal translocations and other chromosomal aber-
rations induced in spermatogonia of the treated males
(Leonard, 1977).
To examine any morphological abnormalities of sperm, the
animals caudae epididymides were removed, dissected and
sperm were processed for ﬁxation and stained with 1% eosin
for 10–15 min. Preparation of spermatozoa was performed
according to Wyrobek (1978).
2.6. Photography
All photography was performed using a photographic research
microscope (Olympus Bx41).
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Data were evaluated by the Student’s t-test (Byrkit, 1980) and
by an analysis of variance (two-way ANOVA) to determine the
signiﬁcance of differences between groups.3. Results
3.1. Mitotic index (M.I.) and cell cycle kinetics
The M.I. data are shown in Table 1. The results indicate a de-
creased M.I. with an increase in the dose of MQ, suggesting a
dose–response relationship. However, these dose effects were
not statistically signiﬁcant. Percentages of cells in metaphase
were not affected by MQ, but the percentages of cells entering
mitosis decreased by about 17–29% in the groups treated with
20 mg/kg at all assay times. Regarding the dose 40 mg/kg,
there was an even greater decrease in the percentage of cells
entering mitosis of about 21–31% at all assay times. Also,
there was a notable recovery in mitotic activities at the ﬁrst
and third weeks post treatment, approaching the control index.
The cell cycle kinetics data are given in Fig. 1. There was a
notable recovery of bone marrow cells toward normal cell cy-
cle kinetics starting 72 h post treatment; this remained stable
until 3 weeks post treatment.
3.2. Analysis of chromosomal aberrations in bone marrow cells
and spermatocyte cells
The effects of the two doses (20 and 40 mg/kg) of MQ on the
incidences of different types of chromosomal aberrations in-
duced in bone marrow cells were examined at 24, 48 and
72 h and 1, 2 and 3 weeks post treatment. At 24 h interval post
treatment with 20 mg/kg of MQ the percentages of total aber-
rant cells, chromatid and chromosome gaps, centromeric chro-
mosome break and centromeric fusion showed a signiﬁcant
increase (p< 0.05) (28.4, 18.8, 10.4, 17.6, and 5.2, respectively)
and when treated with 40 mg/kg of MQ a signiﬁcant increase
in the percentage of total aberrant cells, chromatid gaps, chro-
matid breaks, fragment, centromeric chromosome breaks, and
centromeric fusion when compared to the control group (19.2,
14, 1.2, 3.2, 16, and 2.8, respectively) (Fig. 2 and Plates 1 and
2). The two-way ANOVA for comparison between groups rep-
resented in Table 2 showed signiﬁcant differences in the per-Table 1 Meﬂoquine (MQ) induced changes in mitotic index (M.I.)
Doses of MQ No. of dividing cells and % at diﬀerent assay tim
24 h 48 h 72 h
Control 0 mg/kg 958.6 ± 134.3 996.8 ± 49.2 954 ± 95
47.9% 49.8% 47.7%
20 mg/kg 779.6 ± 22.5a 778.4 ± 15.2a 687.4 ±
39% 38.9% 34.4%
40 mg/kg 686.6 ± 29.7a 683.8 ± 20.8a 700 ± 29
34.3% 34.2% 35%
Five mice per group.
Two thousand cells counted per animal.
a Signiﬁcant at 0.05 level.centages of total chromatid gaps and total centromeric
chromosome breaks between treated and control groups at
six sampling times.
Fig. 3 summarizes the results of the spermatocyte diakinesis
metaphase-1 assay obtained post treatment with both doses of
MQ compared with controls. The induced chromosomal aber-
ration assayed 24 h post treatment was much higher than those
assayed from 1 to 5 weeks. The results indicate that primary
spermatocytes are the most affected stage of meiosis whereas
other stages are equally affected by the MQ treatment analysis
of variance (two-way ANOVA) between groups treated with
20, 40 mg/kg of MQ at six sampling times. Signiﬁcant
(p< 0.05) differences in the percentages of total X–Y univa-
lents and non-signiﬁcant values for total fragments (minutes)
are presented in Table 3 and Plate 3.
3.3. Analysis of sperm head and tail abnormalities of mice
treated with meﬂoquine
The results of sperm head and tail abnormalities in mice trea-
ted with MQ for 1, 2, 3, 4, 5, and 6 weeks post treatment
showed statistically signiﬁcant increase with increasing dosage
over the whole assay time (Table 4). Higher incidences were
observed at the ﬁrst week post treatment. The increase of the
total abnormal head was statistically signiﬁcant (p< 0.05).
The most signiﬁcant increase was noted in the groups treated
with 40 mg/kg and assayed 2, 4, 5 weeks post treatment. The
two-way ANOVA, for comparison between groups showed
signiﬁcant differences in the percentages of total abnormal
sperm using 20, 40 mg/kg of MQ at 1, 2, 3, 4, 5, and 6 weeks
post treatment. These data are presented in Table 5.
4. Discussion
This study assessed and evaluated the potential cytotoxic and
genotoxic effects of two doses of the antimalarial drug MQ
in male mice using a number of parameters. The M.I. de-
creased with an increased dose of antimalarial drug MQ, sug-
gesting a dose–response relationship. However, these dose
effects were statistically not signiﬁcant. A notable recovery
was also recorded in mitotic activities during the ﬁrst and third
weeks post treatment. The percentages of cells at metaphase
was not affected by MQ, but the percentage of cells entering
mitosis decreased by about 17–29% in mice treated with
20 mg/kg MQ at all assay periods. There was an even greaterin bone marrow cells of mice.
e
1 week 2 weeks 3 weeks
.2 950.8 ± 108.7 904.6 ± 67.7 1004.8 ± 136.9
47.5% 45.2% 50.2%
69.2a 805.6 ± 75.5a 711.2 ± 110.9a 800.4 ± 50a
40.3% 35.6% 40%
.6a 720.4 ± 29.6a 662 ± 63a 750.4 ± 34.2a
36% 33% 37.5%
Figure 1 Effect of meﬂoquine (MQ) on cell cycle kinetics assayed 24, 48 and 72 h; 1, 2 and 3 weeks.
Figure 2 Effect of meﬂoquine (MQ) on the incidences of
different types of chromosomal aberrations induced in bone
marrow cells of mice assayed 24, 48, 72 h; 1, 2 and 3 weeks.
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mice treated with 40 mg/kg MQ. This indicates that, when cells
suffer genetic damage, the cell cycle kinetics change in such a
way that cells are arrested at different cell cycle check points
at S phase and M phase (Tobey, 1975; Keiser et al., 2011).
The decrease in M.I. could be explained as a result of cell
cycle delay, where cells are arrested in G2, resulting in an accu-
mulation of large number of cells. This cell cycle delay appears
to be reversible, as the differences in the percentage of cells in
interphase between treated and control groups reduced slowly
over time. Data obtained in this study also show a notable
recovery of bone marrow cells toward normal cell cycle kinet-
ics starting 72 h post treatment and remaining stable until 3
weeks post treatment, for the two doses of MQ (Zhou and Ell-
edge, 2000; Fryauff et al., 2007).
Analysis of the frequency of chromosomal aberrations indi-
cated a 10- to 14-fold increase in frequency above the sponta-neous level in mice treated with both doses of MQ which
indicates a potential mutagenic action of the drug. This is also
well illustrated by the increase in frequency of aberrant cells
analyzed 24 and 48 h post treatment. Frequencies of induced
chromosomal aberrations at 72 h post treatment signiﬁcantly
decreased compared to 24 and 48 h post treatment, but were
still 4–6 times higher than the spontaneous level. These results
clearly show a dose–response relationship at the assayed times.
It is also evident that repair mechanisms to eliminate the dam-
aged chromosomes began operating shortly after treatment.
Every single type of observed chromosomal aberration be-
haved similar to the trend represented by total aberrant cells.
The high frequency of centrometric chromosome breaks ob-
served illustrates a high sensitivity of heterochromatic DNA
regions to MQ or its metabolites (Friedberg et al., 2006).
The levels of chromosomal aberrations induced by MQ re-
mained stable 3 days after treatment, and over a period of
3 weeks. Centrometric fusions involving two chromosomes
were the only type of structural aberrations that remained at
signiﬁcantly higher levels than controls at almost all assay
times. This reﬂects either stability of the induced chromosome
abnormality or persistence of the abnormality in differentiated
bone marrow cells.
The data presented in this study are in contrast with the
previous results obtained by Grisolia and Takahashi (1994).
However, they are in agreement with the ﬁndings of Chatterjee
et al. (1998), who reported that MQ induced statistically signif-
icant increase in sister chromatid exchanges (1.5-fold) and
chromosomal aberrations (2- to 3-fold) in bone marrow cells
of mice at the highest dose tested (100 mg/kg intra-peritone-
ally). It must be emphasized that this study applied different
battery test systems, such as spermatocyte diakinesis meta-
phase-1 and sperm abnormalities that have not been reported
in other studies. However, the negative reports of the mutage-
nicity of MQ may be due to the different methods of adminis-
tration to the drug (Akerele and Obaseiki-Ebor, 2002).
Davidson et al. (1975) and Schupbach (1979) reported that
Plate 1 Bone marrow metaphase spread showing chromosome break from male mouse treated with (A) 20, (B) 40 mg/kg of meﬂoquine
and assessed 2 weeks and 24 h post treatment.
Plate 2 Bone marrow metaphase spreads showing centromeric fusions, and centromeric breaks from male mouse treated with (C and D)
40 mg/kg of meﬂoquine assessed 24 and 48 h, respectively, post treatment.
Table 2 Comparison between groups in bone marrow cells of mice treated with meﬂoquine (MQ).
Comparison between groups F-test value
% of total chromatid gaps % of total centromeric chromosome break
Control (0 mg/kg) 2.7 0
20 mg/kg 10.8a 10.9a
40 mg/kg 14.4a 14.5a
Five mice were used per dose.
Fifty cells counted per mouse.
Two hundred and ﬁfty cells counted per groups.
a Signiﬁcant at 0.05 level.
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non-mutagenic compound. The results obtained in the present
study suggest that spermatids and secondary spermatocytes
are moderately sensitive to the action of MQ at the two treated
doses (20 and 40 mg/kg bw) in comparison to primary sper-
matocytes which are more sensitive while the spermatogonia
are highly sensitive. The highest percentage of abnormal sperm
was recorded in the ﬁrst week of observation, indicating that
spermatogonial stem cells in the seminiferous tubules are also
affected by the drug. Whether this damage would be elimi-
nated over a period of time could be judged by an extension
of the observation period through 4–5 spermatogenic cycles.Results of the analysis of diakinesis metaphase-1 spermato-
cytes showed a signiﬁcant increase in the total number of aber-
rant cells, X–Y univalent, and fragments at all assay times. It is
obvious that spermatocytes exposed directly to MQ showed
the highest incidence in aberrations. Spermatocytes assayed
1–6 weeks post treatment showed a notable decrease in the
incidence of aberrations which suggest that the stages of sper-
matogenesis preceding primary spermatocytes formation are
less sensitive to MQ treatment or that signiﬁcant repair of in-
duced chromosomal damage has taken place. The result also
suggests that the high dose of 40 mg/kg was more effective in
inducing chromosomal aberrations. The efﬁciency of the
Figure 3 Effect of meﬂoquine (MQ) on the incidence of different types of chromosomal aberrations in diakinesis metaphase-1
spermatocytes of mice assayed 24 h; 1, 2, 3, 4 and 5 weeks post treatment.
Table 3 Comparison between groups for total X–Y univalents and total fragments in diakinesis metaphase spermatocytes in mice
treated with meﬂoquine (MQ).
Comparison between groups F-test value
% of total X–Y univalent % of total fragment (min)
Control (0 mg/kg) 0.13 0.13
20 mg/kg 13a 2.53
40 mg/kg 14.9a 3.3
Five mice were used per dose.
Fifty cells counted per mouse.
Two hundred and ﬁfty cells counted per groups.
a Signiﬁcant at 0.05 level.
Plate 3 Spermatocyte diakinesis metaphase-1 spread, showing X–Y univalents and minute, from male mouse treated with (E) 20 and (F)
40 mg/kg of meﬂoquine and assessed 2 weeks and 4 weeks post treatment, respectively.
282 O.H. El-Habit, H.S. Al-Khamashproposed mechanism of repair may be impaired by the quan-
tity of damage, suggesting a limitation of the enzyme repair
systems to cope with the induced damage (Zhou and Elledge,
2000; Farombi, 2006; El-Habit and Al-Khamash, 2010).The results obtained from spermatocyte analysis suggest
that the germ cell line is also affected by MQ, similar to the ef-
fects of MQ on somatic cells of the bone marrow. The impor-
tance of the spermatocyte results is that a high level of
Table 4 Effect of meﬂoquine (MQ) treatment on the frequencies of sperm head and tail abnormalities in male mice.
Assay time % Total abnormal sperm Abnormal head % Abnormal tail
% head without hook % amorphous head
First week
0 mg/kg 4.3 1.3 0.5 2.58
20 mg/kg 12.9a 6a 3.8a 3.1
40 mg/kg 17.2a 7.6a 6a 3.6
Second week
0 mg/kg 3.2 0.9 0.7 1.7
20 mg/kg 11.1a 5.2a 2.9a 2.9a
40 mg/kg 13.8a 5.7a 2.9a 5.2a
Third week
0 mg/kg 4.4 1.1 1.3 2.1
20 mg/kg 8.3a 3.1a 1.7 3.5a
40 mg/kg 12.9a 6a 3.8a 3.1
Fourth week
0 mg/kg 3.7 1 1.1 1.6
20 mg/kg 7.3a 2.6a 1.6 3.1a
40 mg/kg 9.8a 3.2a 2.5a 4.1a
Fifth week
0 mg/kg 3.8 1.2 0.5 2.1
20 mg/kg 6.4a 2.1a 1.5a 2.8
40 mg/kg 8.6a 2.8a 1.7a 4.1a
Sixth week
0 mg/kg 3.1 0.9 0.6 1.6
20 mg/kg 5 1.6a 1a 2.4
40 mg/kg 6.8a 2.3a 1.4a 3.1a
Five mice were used per dose.
One thousand sperm counted per mouse.
a Signiﬁcant at 0.05 level.
Table 5 Comparison between groups of mice treated with meﬂoquine (MQ) for total abnormal sperm.
Treatment F-test value
% of total abnormal sperm % of total head without hook % of total amorphous head % of total abnormal tail
Control (0 mg/kg) 3.8 1.02 0.8 1.9
20 mg/kg 8.5a 3.4a 2.1a 2.96
40 mg/kg 11.5a 4.6a 3.04a 3.9a
Five mice were used per dose.
One thousand sperm counted per mouse.
Five thousand counted per groups.
Two-way ANOVA.
a Signiﬁcant at 0.05 level.
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genesis, from spermatogonial stages until 6 weeks later, thus
providing a high possibility of transmitting these chromosomal
aberrations to the gamete cells.
These conclusions draw attention to the potential mutage-
nicity of MQ to future generations. The teratogenicity of
MQ has been previously demonstrated in animals at doses
which are higher than the therapeutic doses that are recom-
mended for humans (Zaneveld and Polakoski, 1977; Haward,
1996). In addition, Vanhaumere et al. (1998) reported congen-
ital malformations in children born to mothers who were on
MQ therapy at different trimesters during pregnancy. This is
an important consideration when prescribing treatment to wo-men of childbearing age. These patients should be warned of
the possible risk associated with MQ treatment. Patients on
MQ should not conceive for a considerable period of time after
cessation of the treatment, to ensure that the germ cell lines are
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